skip to content

Principal Investigators: Carola-Bibiane Schönlieb and Evis Sala

This project has its own website.

 

Approximately 7,400 women are diagnosed with ovarian cancer every year in the UK [1] and 300,000 worldwide [2]. Medical imaging is routinely used for diagnosis and treatment monitoring of patients with solid tumours and is currently the only available technique for noninvasively assessing treatment response taking into account the overall tumour burden and its spatial and temporal heterogeneity, which in turn are associated with outcome [3]. Currently, image segmentation and evaluation are mostly performed manually and semiquantitatively. The advent of modern computing and the availability of large digital image databanks have led to development of quantitative, data-driven, machine-learning-based medical image analysis methods (radiomics) which have shown great promise in facilitating a deeper understanding of tumour biology, capturing tumour heterogeneity and monitoring tumour evolution and therapy response [4-6]. However, the robustness and generalisability of the radiomics results depend on standardisation of CT instrumentation, data acquisition protocols, choice of reconstruction algorithm, pixel size, etc. [6, 7] which typically vary widely in routine clinical practice.

 

This project addresses the above challenges and provides a robust image analysis pipeline that improves significantly on the performance and predictive power of current radiomics metrics, ultimately improving clinical decisions and patient outcomes:

  • It exploits the power of novel deep neural networks to produce uniform and homogeneous images.

  • It seamlessly integrates image reconstruction with subsequent steps like semantic segmentation (pixel-wise classification) and radiomics analysis.

  • It is integrated in patient’s clinical workflow, providing accurate dynamic quantification of tumour burden that can be used to make real time treatment decisions in both the clinic and MDT settings.

 

  1. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancertype/ovarian-cancer#heading-Zero, Accessed November 2018
  2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed November 2018.
  3. Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, Aghajanian C, Hricak H, Deasy J, Snyder A, Sala E. A novel representation of inter-site tumor heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 2017;27(9):3991-4001.
  4. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563-77.
  5. Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, Weigelt B, Vargas HA. Unraveling tumor heterogeneity using next generation imaging: radiomics, radiogenomics and habitat imaging. Clin Radiol 2016; 72 (1): 3-10.
  6. Sanduleanu S, Woodruff HC, de Jong EEC, van Timmeren JE, Jochems A, Dubois L, Lambin P. Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score. Radiother Oncol. 2018 Jun;127(3):349-360.
  7. Shaikh F, Franc B, Sala E, Awan O, Hendrada K, Halabi S, Mohiuddin S, Malik S, Hadley D, Shrestha R. Translational radiomics – defining the strategy pipeline & considerations for application - part I: from methodology to clinical implementation. J Am Coll Radiol. 2018;15(3 Pt B):538-542.